Australia markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
36.65+0.19 (+0.52%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close36.46
Bid36.50 x 3000
Ask36.65 x 900
Day's range36.31 - 36.67
52-week range33.26 - 43.18
Avg. volume6,126,350
Market cap91.847B
Beta (5Y monthly)0.36
PE ratio (TTM)11.69
EPS (TTM)3.14
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield2.11 (5.79%)
Ex-dividend date18 Feb 2021
1y target est46.57
  • Editor's pick
    Yahoo Finance Video

    Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor

    Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.

  • Motley Fool

    Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

    GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.

  • 3 Stocks That Could Suffer if Biden Gives In to This Pressure
    Motley Fool

    3 Stocks That Could Suffer if Biden Gives In to This Pressure

    A proposal currently before the World Trade Organization would waive patent rights on COVID-19 vaccines and treatments in an effort to help low-income nations. Several top Democrats appear to support the move, although the Biden administration has yet to state a position publicly. Despite the push, the president may be hesitant to override patents for pharmaceuticals.